198 related articles for article (PubMed ID: 10690390)
1. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
Sarris AH; Hagemeister F; Romaguera J; Rodriguez MA; McLaughlin P; Tsimberidou AM; Medeiros LJ; Samuels B; Pate O; Oholendt M; Kantarjian H; Burge C; Cabanillas F
Ann Oncol; 2000 Jan; 11(1):69-72. PubMed ID: 10690390
[TBL] [Abstract][Full Text] [Related]
2. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.
Rodriguez MA; Pytlik R; Kozak T; Chhanabhai M; Gascoyne R; Lu B; Deitcher SR; Winter JN;
Cancer; 2009 Aug; 115(15):3475-82. PubMed ID: 19536896
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
Sarris AH; Phan A; Goy A; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Medeiros LJ; Samuels B; Mesina O; Bleyer AW; Cabanillas F
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):27-31. PubMed ID: 12199630
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
Sarris AH; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Younes A; Mesina O; Cabanillas F; Medeiros LJ; Samuels B
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
[TBL] [Abstract][Full Text] [Related]
7. Infusional vinorelbine in relapsed or refractory lymphomas.
Sarris AH; Psyrri A; Hagemeister F; Romaguera J; McLaughlin P; Rodriguez MA; Bachier C; Younes A; Mesina O; Oholendt M; Medeiros LJ; Samuels B; Adams LM; Cabanillas F
Leuk Lymphoma; 2000 Oct; 39(3-4):291-9. PubMed ID: 11342309
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI
J Clin Oncol; 1998 Feb; 16(2):574-8. PubMed ID: 9469343
[TBL] [Abstract][Full Text] [Related]
10. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Thomas DA; Sarris AH; Cortes J; Faderl S; O'Brien S; Giles FJ; Garcia-Manero G; Rodriguez MA; Cabanillas F; Kantarjian H
Cancer; 2006 Jan; 106(1):120-7. PubMed ID: 16331634
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
13. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
[TBL] [Abstract][Full Text] [Related]
14. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Portlock CS; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz AD; O'Brien JP; Moskowitz C; Norton L; Yahalom J; Straus DJ; Bertino JR
Ann Oncol; 2004 Oct; 15(10):1495-503. PubMed ID: 15367410
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
[TBL] [Abstract][Full Text] [Related]
16. Vincristine liposomal--INEX: lipid-encapsulated vincristine, onco TCS, transmembrane carrier system--vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI.
Drugs R D; 2004; 5(2):119-23. PubMed ID: 15293876
[TBL] [Abstract][Full Text] [Related]
17. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
18. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.
McBride NC; Cavenagh JD; Ward MC; Grant I; Schey S; Gray A; Hughes A; Mills MJ; Cervi P; Newland AC; Kelsey SM
Leuk Lymphoma; 2001 Jun; 42(1-2):89-98. PubMed ID: 11699226
[TBL] [Abstract][Full Text] [Related]
19. Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma.
Tulpule A; Rarick MU; Kolitz J; Bernstein J; Myers A; Buchanan LA; Espina BM; Traynor A; Letzer J; Justice GR; McDonald D; Roberts L; Boswell W; Nathwani B; Levine AM
Ann Oncol; 2001 Apr; 12(4):457-62. PubMed ID: 11398876
[TBL] [Abstract][Full Text] [Related]
20. [The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
Vivanco Martínez JL; López Pérez J; Melero Moreno C; Torres Valdivieso MJ; Palacios López ME; Contra Gómez T; Martín Ramos N; Bernacer Borja M; Gil López C; Valverde Moreno F
An Esp Pediatr; 1998 Dec; 49(6):603-8. PubMed ID: 9972623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]